Legend Biotech CEO Ying Huang On Moving Fast In the BCMA CAR-T Race

Chinese Firm Is Partnered With Second Place Contender Janssen In US

 
• By Mandy Jackson
  
Generate a summary of this article
Listen to this article
Beta

Ying Huang was named CEO as his predecessor came under investigation in China and as partner Janssen was getting closer to seeking US FDA approval for its lead CAR-T therapy.

Cars in road race
Legend's cilta-cel partner Janssen lags BCMA CAR-T leader BMS by a matter of months • Source: Shutterstock

Legend Biotech Corp. has moved its chimeric antigen receptor T-cell (CAR-T) therapy programs forward with impressive speed. The first patient was treated with the B-cell maturation antigen (BCMA)-targeting ciltacabtagene autoleucel in China in 2016, the first pivotal trial launched in 2018 and just before the end of 2020 the company’s partner Janssen Pharmaceutical Cos. initiated a rolling submission to the US Food and Drug Administration.

However, soon after Legend launched one of the biggest initial public offerings of 2020 in the US by a biopharmaceutical...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.